Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

No role for activated long-term memory in attentional control settings.

Plater L, Giammarco M, Fiacconi C, Al-Aidroos N.

J Exp Psychol Gen. 2019 Jun 24. doi: 10.1037/xge0000642. [Epub ahead of print]

PMID:
31233320
2.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

3.

Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib.

Raimbourg J, Joalland MP, Cabart M, de Plater L, Bouquet F, Savina A, Decaudin D, Bennouna J, Vallette FM, Lalier L.

Mol Cancer Ther. 2017 Aug;16(8):1634-1644. doi: 10.1158/1535-7163.MCT-17-0075. Epub 2017 May 18.

4.

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization.

Vallerand D, Massonnet G, Kébir F, Gentien D, Maciorowski Z, De la Grange P, Sigal-Zafrani B, Richardson M, Humbert S, Thuleau A, Assayag F, de Plater L, Nicolas A, Scholl S, Marangoni E, Weigand S, Roman-Roman S, Savina A, Decaudin D.

PLoS One. 2016 Jul 7;11(7):e0157670. doi: 10.1371/journal.pone.0157670. eCollection 2016.

5.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.

Hatem R, El Botty R, Chateau-Joubert S, Servely JL, Labiod D, de Plater L, Assayag F, Coussy F, Callens C, Vacher S, Reyal F, Cosulich S, Diéras V, Bièche I, Marangoni E.

Oncotarget. 2016 Jul 26;7(30):48206-48219. doi: 10.18632/oncotarget.10195.

6.

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

Hatem R, Labiod D, Château-Joubert S, de Plater L, El Botty R, Vacher S, Bonin F, Servely JL, Dieras V, Bièche I, Marangoni E.

Int J Cancer. 2016 May 15;138(10):2510-21. doi: 10.1002/ijc.29974. Epub 2016 Jan 6.

7.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D.

PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.

8.

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.

Bieche I, Vacher S, Vallerand D, Richon S, Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E, Roman-Roman S, Decaudin D, Dangles-Marie V.

BMC Cancer. 2014 Mar 13;14:178. doi: 10.1186/1471-2407-14-178.

9.

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Némati F, de Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, Berniard A, Vallerand D, Geneste O, de Plater L, Pierré A, Lockhart B, Desjardins L, Piperno-Neumann S, Depil S, Decaudin D.

PLoS One. 2014 Jan 13;9(1):e80836. doi: 10.1371/journal.pone.0080836. eCollection 2014.

10.

The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system.

Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, Cohen P.

Biochem J. 2013 May 1;451(3):427-37. doi: 10.1042/BJ20121651.

11.

Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages.

Clark K, MacKenzie KF, Petkevicius K, Kristariyanto Y, Zhang J, Choi HG, Peggie M, Plater L, Pedrioli PG, McIver E, Gray NS, Arthur JS, Cohen P.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. doi: 10.1073/pnas.1215450109. Epub 2012 Oct 2.

12.

Molecular profiling of patient-derived breast cancer xenografts.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E.

Breast Cancer Res. 2012 Jan 16;14(1):R11.

13.

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.

Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16.

PMID:
22002565
14.

MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases.

Filippi BM, de los Heros P, Mehellou Y, Navratilova I, Gourlay R, Deak M, Plater L, Toth R, Zeqiraj E, Alessi DR.

EMBO J. 2011 May 4;30(9):1730-41. doi: 10.1038/emboj.2011.78. Epub 2011 Mar 18.

15.

Novel cross-talk within the IKK family controls innate immunity.

Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P.

Biochem J. 2011 Feb 15;434(1):93-104. doi: 10.1042/BJ20101701.

PMID:
21138416
16.

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.

de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E.

Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28.

17.

A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.

Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.

Anticancer Drugs. 2010 Nov;21(10):927-31. doi: 10.1097/CAD.0b013e32833db887.

PMID:
20827173
18.
19.

The selectivity of protein kinase inhibitors: a further update.

Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.

Biochem J. 2007 Dec 15;408(3):297-315.

20.

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF.

Clin Cancer Res. 2007 Jul 1;13(13):3989-98.

21.

Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide.

Windheim M, Lang C, Peggie M, Plater LA, Cohen P.

Biochem J. 2007 Jun 1;404(2):179-90. Erratum in: Biochem J. 2008 Feb 1;409(3):789.

Supplemental Content

Loading ...
Support Center